UBS analyst Ashwani Verma raised the firm’s price target on United Therapeutics (UTHR) to $415 from $385 and keeps a Buy rating on the shares. UBS is modeling a 50% probability of success for the Tyvaso Phase 3 study in Idiopathic Pulmonary Fibrosis, but UBS sees a favorable risk/reward on the stock as downside should be minimized by United’s Accelerated Share Repurchase, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on UTHR:
- United Therapeutics’ Promising Phase 3 Study on Inhaled Treprostinil for Pulmonary Fibrosis
- United Therapeutics’ Phase 3 Study on Inhaled Treprostinil for Pulmonary Fibrosis: A Potential Game-Changer
- United Therapeutics’ Inhaled Treprostinil Study: A Potential Game-Changer for IPF Treatment
- DDD Lawsuit Alert! Class Action Lawsuit Against 3D Systems Corporation
- United Therapeutics Launches $1 Billion Share Buyback